Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AN2 Therapeutics, Inc.ANTX · Entity 1085 | See Remarks | July 08, 2026 | July 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AN2 Therapeutics, Inc.
Report date July 08, 2026 · Filed July 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 206,554 |
Reported balance
After 2026-07-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-08 · Sale · Disposed 5,945 · Balance 206,554 F1: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on July 1, 2026. F2: Includes a balance of (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (c) 58,500 RSUs which vest as follows 1/4th of the RSUs vest annually over four years from January 1, 2025 and (d) 50,000 RSUs which vest as follows: 1/4th of RSUs vest annually over four years from January 1, 2026, in each case subject to the Reporting Person's continuous service as of such date. F3: Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on July 1, 2026.
F2: Includes a balance of (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (c) 58,500 RSUs which vest as follows 1/4th of the RSUs vest annually over four years from January 1, 2025 and (d) 50,000 RSUs which vest as follows: 1/4th of RSUs vest annually over four years from January 1, 2026, in each case subject to the Reporting Person's continuous service as of such date.
F3: Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2026 Filed Jul 10, 2026 18:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 5,945 | $4.17 | $24,802.54 |
DisclosureSEC source: 0001193125-26-301092 · ownership.xml · nonDerivative · entry 1 Eizen Joshua M · CIK 0001949621 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,554 F1 · shares: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on July 1, 2026. F2 · balance_after: Includes a balance of (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (c) 58,500 RSUs which vest as follows 1/4th of the RSUs vest annually over four years from January 1, 2025 and (d) 50,000 RSUs which vest as follows: 1/4th of RSUs vest annually over four years from January 1, 2026, in each case subject to the Reporting Person's continuous service as of such date. F3 · balance_after: Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2026. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 19:06 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Disposition to issuerStock Option (right to buy) · Derivative | 50,150 | Not disclosed Strike: $14.29 | Not disclosed |
DisclosureSEC source: 0001193125-26-120210 · ownership.xml · derivative · entry 4 Eizen Joshua M · CIK 0001949621 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,150 shares Expires 2033-02-14 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 19:06 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 50,150 | Not disclosed Strike: $3.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120210 · ownership.xml · derivative · entry 3 Eizen Joshua M · CIK 0001949621 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,150 Underlying: Common Stock · 50,150 shares Expires 2033-02-14 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 19:06 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Disposition to issuerStock Option (right to buy) · Derivative | 92,000 | Not disclosed Strike: $17.88 | Not disclosed |
DisclosureSEC source: 0001193125-26-120210 · ownership.xml · derivative · entry 2 Eizen Joshua M · CIK 0001949621 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 92,000 shares Expires 2032-10-13 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares shall vest on the anniversary of September 29, 2022, and the remainder of the shares shall vest ratably monthly over the subsequent 36 months, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 19:06 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 92,000 | Not disclosed Strike: $3.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120210 · ownership.xml · derivative · entry 1 Eizen Joshua M · CIK 0001949621 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,000 Underlying: Common Stock · 92,000 shares Expires 2032-10-13 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares shall vest on the anniversary of September 29, 2022, and the remainder of the shares shall vest ratably monthly over the subsequent 36 months, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 16:41 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001193125-26-064176 · ownership.xml · derivative · entry 2 Eizen Joshua M · CIK 0001949621 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-02-19 F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 16:41 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-064176 · ownership.xml · nonDerivative · entry 1 Eizen Joshua M · CIK 0001949621 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,499 F1 · shares: Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. F2 · balance_after: Includes a balance of (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 60,000 RSUs which vest as follows: 25% of the RSUs vest on January 1, 2025, 50% of the RSUs vest on January 1, 2026, and 25% of the RSUs vest on July 1, 2026, (c) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, and (d) 58,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person's continuous service through each applicable vesting date. F3 · balance_after: Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2025. Read SEC document |
| January 06, 2026 Filed Jan 7, 2026 20:12 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 6,931 | $1.01 | $7,014.17 |
DisclosureSEC source: 0001193125-26-006763 · ownership.xml · nonDerivative · entry 2 Eizen Joshua M · CIK 0001949621 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,499 F1 · shares: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2026. F3 · balance_after: Includes (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 60,000 RSUs which vest as follows: 25% of the RSUs vest on January 1, 2025, 50% of the RSUs vest on January 1, 2026, and 25% of the RSUs vest on July 1, 2026, (c) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, and (d) 58,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person's continuous service as of such date. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 20:12 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 17,923 | $1.00 | $17,948.09 |
DisclosureSEC source: 0001193125-26-006763 · ownership.xml · nonDerivative · entry 1 Eizen Joshua M · CIK 0001949621 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,430 F1 · shares: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2026. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.001 to $1.003 per share. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 60,000 RSUs which vest as follows: 25% of the RSUs vest on January 1, 2025, 50% of the RSUs vest on January 1, 2026, and 25% of the RSUs vest on July 1, 2026, (c) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, and (d) 58,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person's continuous service as of such date. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 18:12 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 2,819 | $1.14 | $3,213.66 |
DisclosureSEC source: 0001193125-25-270255 · ownership.xml · nonDerivative · entry 1 Eizen Joshua M · CIK 0001949621 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,353 F1 · shares: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on November 4, 2025. F2 · balance_after: Includes, in accordance with the original terms, (a) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 (b) 22,500 RSUs which vest as follows: 1/3rd of the RSUs vest annually over three years from January 1, 2025 and (c) 45,000 RSUs which vest as follows: 2/3rd of the RSUs vest on January 1, 2026 and 1/3rd of the RSUs vest on July 1, 2026, subject to the Reporting Person's continuous service as of such date. F3 · balance_after: Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on September 30, 2025. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 16:22 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 117,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0000950170-25-030042 · ownership.xml · derivative · entry 2 Eizen Joshua M · CIK 0001949621 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,000 Underlying: Common Stock · 117,000 shares Expires 2035-02-25 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 16:22 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 58,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-030042 · ownership.xml · nonDerivative · entry 1 Eizen Joshua M · CIK 0001949621 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,172 F1 · shares: Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date. F2 · balance_after: Includes (a) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 (b) 22,500 RSUs which vest as follows: 1/3rd of the RSUs vest annually over three years from January 1, 2025 and (c) 45,000 RSUs which vest as follows: 2/3rd of the RSU vest on January 1, 2026 and 1/3rd of the RSUs vest on July 1, 2026, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 19:57 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 9,663 | $1.34 | $12,958.08 |
DisclosureSEC source: 0000950170-25-003152 · ownership.xml · nonDerivative · entry 1 Eizen Joshua M · CIK 0001949621 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,672 F1 · shares: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2025. F2 · balance_after: Includes (a) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 (b) 22,500 RSUs which vest as follows: 1/3rd of the RSUs vest annually over three years from January 1, 2025 and (c) 45,000 RSUs which vest as follows: 2/3rd of the RSU vest on January 1, 2026 and 1/3rd of the RSUs vest on July 1, 2026, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| November 04, 2024 Filed Nov 5, 2024 16:51 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 63,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0000950170-24-121591 · ownership.xml · derivative · entry 2 Eizen Joshua M · CIK 0001949621 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 63,000 shares Expires 2034-11-03 F4 · derivative.exercise_date: The shares subject to the option are exercisable and vest as follows: 1/48th of the shares vest and becomes exercisable monthly over four years from November 4, 2024 until fully vested and exercisable on November 4, 2028, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| November 04, 2024 Filed Nov 5, 2024 16:51 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 31,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-121591 · ownership.xml · nonDerivative · entry 1 Eizen Joshua M · CIK 0001949621 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,335 F1 · shares: Represents a grant of restricted stock units ("RSUs"). RSUs vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 until fully vested on November 4, 2028, subject to the Reporting Person's continuous service as of such date. F2 · balance_after: Includes (a) a balance of 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024 and (b) a balance of 60,000 RSUs which vest as follows: 1/4th of the RSUs vest on January 1, 2025, 1/2 of the RSUs vest on January 1, 2026 and 1/4th of the RSUs vest on July 1, 2026, subject to the Reporting Person's continuous service as of such date. F3 · balance_after: Reflects the adjusted total which includes the purchase of 2,386 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2024 and 2 shares under the Issuer's 2022 Employee Stock Purchase Plan on September 30, 2024. Read SEC document |
| July 10, 2024 Filed Jul 12, 2024 16:13 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-083200 · ownership.xml · nonDerivative · entry 1 Eizen Joshua M · CIK 0001949621 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,833 F1 · shares: Represents a grant of restricted stock units ("RSUs"). RSUs vest as follows: 25% vest on January 1, 2025, 50% vest on January 1, 2026 and 25% vest on July 1, 2026, subject to the Reporting Person's continuous service as of such date. F2 · balance_after: Includes a balance of 30,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. F3 · balance_after: Reflects the adjusted total which includes the purchase of 2,386 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2024. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 19:28 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000168 · form4.xml · derivative · entry 2 Eizen Joshua M · CIK 0001949621 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-03-14 F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 19:28 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000168 · form4.xml · nonDerivative · entry 1 Eizen Joshua M · CIK 0001949621 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,447 F1 · shares: These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. F2 · balance_after: Reflects the adjusted total which includes the purchase of 1,207 shares under the AN2 Therapeutics, Inc. 2022 Employee Stock Purchase Plan on March 31, 2023. F3 · balance_after: Reflects the adjusted total which includes the purchase of 1,240 shares under the AN2 Therapeutics, Inc. 2022 Employee Stock Purchase Plan on September 29, 2023. Read SEC document |
| March 15, 2024 Filed Mar 29, 2024 16:18 UTC Amendment | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000194 · form4.xml · nonDerivative · entry 1 Eizen Joshua M · CIK 0001949621 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,447 F1 · shares: Previously reported on a Form 4 filed on March 18, 2024. As amended, the vesting schedule for the restricted stock units is as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 19:24 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 50,150 | $0.00 Strike: $14.29 | $0.00 |
DisclosureSEC source: 0000899243-23-005554 · doc4.xml · derivative · entry 1 Eizen Joshua M · CIK 0001949621 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,150 Underlying: Common Stock · 50,150 shares Expires 2033-02-14 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from January 1, 2023. Read SEC document |
| October 14, 2022 Filed Oct 28, 2022 18:03 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 92,000 | $0.00 Strike: $17.88 | $0.00 |
DisclosureSEC source: 0000899243-22-034442 · doc4.xml · derivative · entry 1 Eizen Joshua M · CIK 0001949621 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,000 Underlying: Common Stock · 92,000 shares Expires 2032-10-13 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares shall vest on the anniversary of September 29, 2022, and the remainder of the shares shall vest ratably monthly over the subsequent 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.